B19 CZV OCULAR
The best prophylactic tool for conjunctival administration to control brucellosis in endemic areas through mass vaccination programs in cattle.
VACCINE OF CHOICE FOR BOVINE BRUCELLOSIS
In addition to its high zoonotic impact, brucellosis is a major cause of miscarriage and infertility in cattle, which results in significant economic losses for farmers. Vaccination is the most effective prevention method to reduce the incidence of brucellosis in endemic areas.
B19 CZV OCULAR is a freeze-dried suspension of the live Brucella abortus strain B-19 in the smooth phase for the immunization of cattle against brucellosis induced either by Brucella abortus or Brucella melitensis.
Manufactured in compliance with OIE and EU standards, B19 CZV OCULAR is the first anti-brucellosis vaccine registered for conjunctival administration to cattle.
Moreover, B19 CZV OCULAR is safe enough even in adult cows, being the best prophylactic tool to control the disease in endemic areas through mass vaccination programs. When applied in young replacement heifers and combined with suitable diagnostic methods, it can be used successfully in test and slaughter eradication programs.
Is the best prophylactic tool to control the disease in endemic areas through mass vaccination programs.
B19 CZV OCULAR combines a perfect dissolution of the freeze-dried content with a suitable solvent (stained with Patent Blue V to better ensure correct application in the conjunctival mucosa) and the high dosage precision of the dropper, allowing easy vaccine application as a single drop placed on the corneal surface.
Beef cattle: application of the B19 CZV Ocular
Dairy cattle: application of the B19 CZV Ocular
Vaccine administration video
MOST PRACTICAL VACCINE TO CONTROL BOVINE BRUCELLOSIS
When the goal is to keep brucellosis prevalence to a minimum, B19 CZV OCULAR is the vaccine of choice for mass vaccination because:
- A single dose confers suitable immunity in par with that induced by the classical subcutaneous vaccine.
- Except in bulls (where safety has not been fully assessed), it can be used in both young and adult animals, including pregnant and lactating cows, causing minimal side effects (less than 3% of induced miscarriages and shedding of the vaccine strain in milk).
- A program based on the conjunctival vaccination of the whole population (with the exception of bulls) repeated every two years for at least one animal generation (5 to 8years), is the most practical, affordable, and effective strategy to control the disease. As an alternative, vaccination of the whole population the first year and then only young replacement heifers in the ensuing years will also control the disease, reducing the prevalence to a minimum compatible with the further application of a test and slaughter eradication program.
SUITABLE IN BOTH MASS VACCINATION
AND ERADICATION PROGRAMS
Unlike the classical B-19 subcutaneous vaccine, B19 CZV OCULAR induces a very weak and short-lasting serological response, which does not interfere in the long term when applied exclusively in young replacement heifers aged 3 to 4 months.
In the absence of secondary antigenic contacts, most vaccinated heifers show negative RBT and CFT brucellosis tests between 6 and 8 months after vaccination. Thus, this weak antibody response minimizes or even abrogates the potential interference in the conventional serological tests used in test and slaughter eradication programs.